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Summary
Interleukin-1 (IL-1) receptor-associatedkinase-4 (IRAK-4)
is a serine/threonine kinase that plays an essential role
in signal transduction by Toll/IL-1 receptors (TIRs).
Here, we report the crystal structures of the phosphor-
ylated human IRAK-4 kinase domain in complex with
a potent inhibitor and with staurosporine to 2.0 and
2.2 A˚, respectively. The structures reveal that IRAK-4
hasaunique tyrosinegatekeeper residue that interacts
with the conserved glutamate from helix aC. Conse-
quently, helix aC is ‘‘pulled in’’ to maintain the active
orientation, and the usual pre-existing hydrophobic
back pocket of the ATP-binding site is abolished. The
peptide substrate-binding site is more open when
compared with other protein kinases due to a marked
movement of helixaG.Thepattern of phosphate ligand
interactions in the activation loop bears a close resem-
blance to that of a tyrosine kinase. Our results provide
insights into IRAK-4 function and the design of selec-
tive inhibitors.
Introduction
Interleukin-1 receptor-associated kinases (IRAKs) are
key components in the signal transduction pathways
mediated by interleukin-1 receptor (IL-1R) and Toll-like
receptors (TLRs) (Janssens and Beyaert, 2003). Al-
though known as serine/threonine kinases, IRAKs be-
long to the tyrosine kinase-like (TLK) family of the human
kinome (Manning et al., 2002). There are four members in
the mammalian IRAK family: IRAK-1 (Cao et al., 1996),
IRAK-2 (Muzio et al., 1997), IRAK-M (Wesche et al.,
1999), and IRAK-4 (Li et al., 2002). Under overexpression
conditions, all IRAKs can mediate the activation of nu-
clear factor-kB (NF-kB) and stress-induced mitogen-
activated protein kinase (MAPK)-signaling cascades.
While all four IRAKs share a similar domain structure,
containing a conserved N-terminal death domain (DD)
and a central kinase domain, only IRAK-1 and IRAK-4
have been shown to have active kinase activity.
While IRAK-1 kinase activity could be dispensable for
its function in IL-1-induced NF-kB activation (Kanakaraj
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tivity for signal transduction (Li et al., 2002; Lye et al.,
2004). Among IRAK family members, IRAK-4 shares
the highest sequence homology with a Drosophila Pelle
protein, an ortholog of mammalian IRAKs. Pelle plays a
role in the Drosophila Toll-signaling pathway and also
requires kinase activity for signal transduction (Shelton
and Wasserman, 1993). Endogenous IRAK-4 interacts
with IRAK-1 and TRAF6 in an IL-1-dependent manner,
but it is not functionally redundant with IRAK-1.
Genetic evidence also supports a role for IRAK-4 in IL-
1R/TLR signaling. IRAK-42/2 mice showed a severe im-
pairment of signaling and cellular responses to IL-1 and
various TLR ligands (Suzuki et al., 2002). In humans, mu-
tations resulting in IRAK-4 deficiency have also been
linked to susceptibility to bacterial infections, especially
recurrent pyogenic bacterial infections (Medvedev et al.,
2003; Picard et al., 2003). The essential function of IRAK-
4 kinase activity in IL-1 signaling was further demon-
strated in two recent publications. One study utilized
IRAK-4-deficient cells and demonstrated that the kinase
activity of IRAK-4 is required for optimal activation of
IRAK-1, NF-kB, and JNK, and for maximal induction of
inflammatory cytokines (Lye et al., 2004). The other
study utilized IRAK-4 mutant variants identified from hu-
man patients with recurrent bacterial infections, in which
IRAK-4 with a truncated kinase domain blocked normal
IL-1 signaling by disrupting formation of the receptor
complex (Medvedev et al., 2005). Given the critical role
of IRAK-4 in IL-1R and TLR signaling, which are central
to the development of autoimmune and inflammatory
diseases, modulation of IRAK-4 kinase activity presents
an attractive therapeutic approach for the treatment of
immune disorders. Elucidation of the three-dimensional
structure of IRAKs will help facilitate the understanding
of the mechanistic role of IRAKs in immunity as well as
the development of specific IRAK inhibitors.
Here, to our knowledge, we report the first crystal
structure of the kinase domain of the phosphorylated,
active form of IRAK-4 (residues 154–460) in complex
with a potent synthetic inhibitor as well as with stauro-
sporine at resolutions of 2.0 and 2.2 A˚, respectively.
The structures reveal that the unique tyrosine gate-
keeper residue in IRAK-4 interacts with the conserved
glutamate from helix aC. As a result, helix aC is ‘‘pulled
in’’ to maintain the active orientation, which abolishes
the usual pre-existing hydrophobic pocket in the back
of the ATP-binding site. Interestingly, the peptide sub-
strate-binding site is more open when compared with ei-
ther serine/threonine or tyrosine protein kinases due to
an unusual marked movement of helix aG, which has
not been observed previously for other protein kinases.
Although IRAK-4 is known as a serine/threonine kinase,
the pattern of phosphate ligand interactions in the acti-
vation loop bears a close resemblance to that of a pro-
tein tyrosine kinase. Our comparative sequence and
structural analysis indicates that IRAK-4 might also
have activity toward tyrosine in addition to serine and
threonine. Furthermore, our study demonstrates that
the ATP-binding site in IRAK-4 has no deep pocket in
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grants an additional opportunity for designing selective
IRAK-4 inhibitors.
Results and Discussion
Overall Structure
The crystal structure of the human IRAK-4 kinase do-
main (residues 154–460 of the full-length protein of 460
amino acids) in complex with a potent inhibitor, com-
pound 1 (Figure 1), was determined by single-wave-
length anomalous dispersion (SAD) at 2.0 A˚ (Table 1).
The main-chain and side-chain atoms of IRAK-4 are vis-
ible for residues 164–458 in the final electron density
map. The staurosporine complex crystallized in the
same space group but with slightly different cell con-
Figure 1. Chemical Structure of Compound 1
Table 1. Statistics of Crystallographic Data and Refinement
Crystal Compound 1 Staurosporine Hg (PCMB)
Wavelength (A˚) 1.0 1.0 1.54
Space group C2 C2 C2
Cell constants (A˚) a = 145.3 a = 141.5 a = 141.8
b = 141.3 b = 139.7 b = 141.8
c = 88.4 c = 87.7 c = 87.6
b = 125.8 b = 123.8 b = 128.0
Resolution (A˚) 2.0 2.2 3.2
Total reflections 1,055,457 694,581 264,479
Unique reflections 92,544 79,301 22,604
Completeness (%) 95.4 99.4 99.3
I/s 13.3 (1.6) 20.5 (3.3) 7.9 (1.8)
Rsym (%) 9.0 (39.2) 6.1 (37.0) 12.1 (50.6)
SAD Phasing
SOLVE FOM (83Hg) 0.29
SOLVE z-score 23.5
Refinement
Rcryst (%) 23.3 20.9
Rfree (%) 29.9 26.1
Rmsd bond
lengths (A˚)
0.021 0.019
Rmsd bond
angles ()
2.11 1.69
Total non-H atoms 9,951 9,520
Rmsd is the root-mean-square deviation from ideal geometry.
Numbers in parentheses are for the highest-resolution shell.
Rsym =
PjIavg 2 Ijj/
P
Ij. R =
PjFo 2 Fcj/
P
Fo, where Fo and Fc are
observed and calculated structure factors, respectively. Rfree was
calculated from a randomly chosen 5% of reflections excluded
from the refinement, and Rcryst was calculated from the remaining
95% of reflections.stants. The two structures are almost identical, with
the exception of a few loops, which include the phos-
phate-binding loop (P loop), partially disordered loop
aC-b3 (residues 216–225), and the activation loop (resi-
dues 337–341) that appears singly phosphorylated in
the staurosporine complex structure.
The overall structure of the IRAK-4 kinase domain
adopts the canonical fold of classical protein kinases,
with the ATP-binding cleft, occupied by the inhibitor,
sandwiched between a bilobal arrangement (Figure 2).
The N-terminal lobe consists mainly of a twisted, five-
stranded antiparallel b sheet and one a helix (aC), and
the larger C-terminal lobe is predominantly a helical.
The IRAK-4 kinase domain structure was solved in its
active form, and it closely resembles active cAMP-
dependent kinase (cAPK) (Zheng et al., 1993) and
lymphocyte-specific tyrosine kinase LCK (Yamaguchi
and Hendrickson, 1996; Zhu et al., 1999). Two residues
on the activation loop, Thr345 and Ser346, are phos-
phorylated in the complex structure with compound 1.
The protein construct of IRAK-4 kinase used yielded
a crystal structure that has extra ordered residues ex-
tending from the N terminus of the kinase domain. This
extra extension (residues 154–190) preceding the N-ter-
minal lobe of the kinase domain was found to be impor-
tant for protein expression as well as for kinase activity
when compared with the full-length protein. Here, the
structure reveals that it forms a short, extra b strand
(b0) (residues 166–168) packed in parallel with the b4
strand, an extra a helix (aB) (residues 169–177), and
then a loop (residues 182–190), which caps the top of
Figure 2. Ribbon Diagram of the IRAK-4 Kinase Domain in Complex
with Inhibitor Compound 1
The N-terminal extension preceding the kinase domain is shown in
magenta. The activation segment is colored in red, and two phos-
phorylated residues, pThr345 and pSer346, are highlighted. Helix
aG and its flanking loops are colored in cyan, and the extra loop be-
tween helices aD and aE is colored in orange. The inhibitor binding in
the ATP cleft is shown as a molecular surface representation
and is color coded green for carbon, blue for nitrogen, and red for
oxygen.
Crystal Structure of IRAK-4 Kinase
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(A) LCK (PDB code: 3LCK) is shown in yellow.
(B) cAPK (PDB code: 1ATP) is shown in light green.
Coloring for IRAK-4 is as in Figure 2.the b sheet in the N-terminal lobe. Helix aB crosses over
the five-stranded b sheet and offers several hydropho-
bic residues for the interaction with the concaved hydro-
phobic surface of the b sheet. Many other protein kinase
structures also reveal such N-terminal extensions that
often pack tightly against the core structure of the ki-
nase domain and become an integral part of the overall
fold (Lei et al., 2005). However, they share no sequence
homology or structural similarity, but they do display
a similar characteristic of presenting hydrophobic inter-
actions to the surface of the b sheet.
Structural comparison of IRAK-4 kinase with other
serine/threonine or tyrosine kinases shows that most
of the conserved structural elements are in good align-
ment (Figure 3). In addition to the N-terminal extension,
three regions display variations, including the loop be-
tween helices aD and aE (residues 276–282, loop aDE),
the activation segment that spans the conserved se-
quence motifs DFG to APE (residues 329–358), and helix
aG (residues 395–406) and its adjoining loops (residues
383–394 and 407–423). The most striking change is in
the region of helix aG, which moves significantly away
from the active site and helix aEF with around a 10 A˚ shift
compared with other protein kinases such as tyrosine
kinase LCK (Yamaguchi and Hendrickson 1996; Zhu
et al., 1999) and serine/threonine kinase cAPK (Zheng
et al., 1993). Such a change has not been reported pre-
viously for other protein kinases.
Activation Loop
The conformation of the doubly phosphorylated activa-
tion loop of IRAK-4 is, in general, similar to that of other
phosphorylated serine/threonine kinases such as cAPK
(Zheng et al., 1993), cyclin-dependent kinase CDK2(Russo et al., 1996), and MAP kinase ERK2 (Canagarajah
et al., 1997) as well as tyrosine kinases such as LCK (Ya-
maguchi and Hendrickson, 1996) and insulin receptor
kinase (IRK) (Hubbard, 1997). While pSer346 points out-
ward to the solvent, and its phosphate group makes no
contacts with protein, pThr345 is folded back toward the
protein core, and its phosphate group is positioned
to compensate a positively charged pocket (Figure 4).
This binding pocket is clustered by three arginine resi-
dues: Arg310, which precedes the catalytic base
Asp311 in the catalytic loop; Arg334, which is the third
residue after the signature DFG motif upstream of the
activation loop; and Arg347, which is also in the activa-
tion loop, but downstream of the two phosphorylated
residues. Surprisingly, only one residue (Arg334) is co-
ordinated directly to the phosphate group of pThr345.
Additional interactions with the phosphate group of
pThr345 are a water-mediated hydrogen bond with
Arg310 of the catalytic loop and a direct hydrogen
bond to the backbone amide nitrogen of Ser346. Such
an interaction pattern diverges from that of other phos-
phorylated serine/threonine-protein kinases, in which
2–3 phosphate-binding ligands are normally observed
(Brown et al., 1999; Canagarajah et al., 1997; Zheng
et al., 1993). Among these positively charged residues,
the ones from the catalytic loop and helix aC are be-
lieved to be important for promoting the correct orienta-
tion and electrostatic environment for the catalytic base
Asp311, as well as for the proper active orientation for
helix aC (Johnson et al., 1996). A single phosphate li-
gand interaction pattern has been reported recently for
a serine/threonine MAP3K TAO2 kinase, in which this
single phosphate interaction is provided by Arg150
from the catalytic loop of TAO2 (Zhou et al., 2004).
Structure
1838In comparison with serine/threonine kinases, fewer
phosphate ligand-binding interactions have been ob-
served for tyrosine protein kinases, such as LCK (Yama-
guchi and Hendrickson, 1996), IRK (Hubbard, 1997),
insulin-like growth factor 1 receptor kinase (IGF1RK)
Figure 4. Comparison of the Activation Loops of IRAK-4, LCK, and
cAPK
(A–C) The activation loop is shown in red. The catalytic loop and helix
aC are in purple for (A) IRAK-4, (B) yellow for LCK, and (C) light green
for cAPK.(Favelyukis et al., 2001), and, more recently, Janus ki-
nase 3 (JAK3) (Boggon et al., 2005). All of these kinases
share a common motif for the phosphate ligand-binding
interaction, i.e., with a single primary phosphate ligand
arginine or lysine in the activation loop, in an equivalent
position to Arg334 of IRAK-4. Interestingly, the pattern
of the phosphate ligand-binding interactions of IRAK-4
is almost identical to that of IRK, a protein tyrosine
kinase, although IRAK-4 is a protein serine/threonine
kinase.
Substrate-Binding Site
A closer comparison with peptide substrate cocrystal
structures of cAPK (Zheng et al., 1993), phosphorylase
kinase (PhK) (Lowe et al., 1997), and IRK (Hubbard,
1997) leads to insights into the characteristics of the
IRAK-4 substrate-binding site. The fold of the P+1
pocket, defined by the downstream surface loop of the
activation loop to helix aEF (residues I348VGTTAYM355),
closely resembles those in cAPK and PhK. Thr351 (cor-
responding to Thr186 in PhK), a conserved threonine
residue in serine/threonine kinases, interacts with cata-
lytic base Asp311 and Lys313 from the catalytic loop
(Figure 5). However, there is a substantial difference in
the nature and size of the binding site in IRAK-4. Instead
of being lined with all hydrophobic residues in the P+1
pocket, such as Val183, Pro187, and Leu190 in PhK,
and Leu198, Pro202, and Leu205 in cAPK, IRAK-4 has
Ile348, Thr352, and Met355 (Figure 5). As a result,
IRAK-4 substrates are likely to adopt a similar conforma-
tion around the P+1 site, but with different specificity. A
large and more polar P+1 residue is preferred for the
interaction with Thr352 in the P+1 loop. Moreover, two
charged residues, Arg347 from the activation loop and
Asp220 from the loop after helix aC, reach the P+2
site. Thus, a polar or charged P+2 residue is preferred
for the IRAK-4 substrate.
It has been shown previously that the activation loop
of IRAK-1 can be phosphorylated by IRAK-4 (Li et al.,
2002). We took the sequence around the potential pri-
mary phosphorylation residue Thr381 in the activation
loop of IRAK-1 (A379RTQT383) and built an IRAK-4 com-
plex model with this putative peptide substrate, based
on the crystal structure of a PhK peptide substrate com-
plex (Lowe et al., 1997), placing residue Thr381 of the
IRAK-1 peptide substrate at the P0 position. The P+1
residue Gln382 suits the P+1 pocket of IRAK-4 very
well in terms of pocket shape complementarity and
interactions.
In addition to the shape/size and hydrophobicity of
the P+1 pocket, the shift of helix aG and its flanking
loops in IRAK-4 also impacts the substrate-binding
site. Typically, the outside of the P+1 pocket is bordered
by residues projecting from helix aG, such as Gln234 in
PhK and Tyr247 in cAPK. However, the dramatic shift
made by helix aG in IRAK-4 offers an open space at
the side of the P+1 pocket and creates a hydrophobic
groove bound by the region of the C-terminal activation
loop, the P+1 loop, and helix aG (Figure 5). Interestingly,
this hydrophobic groove is typically the location for helix
aG of other protein kinases. While helix aG shifts away
from the P+1 site, the loop preceding helix aG actually
shifts closer to the P+1 loop, with Val387 making
van der Waals contact with Ala353 in the P+1 loop. In
Crystal Structure of IRAK-4 Kinase
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(A) The P+1 site of IRAK-4; the activation loop is shown in red.
(B) Molecular surface representation of the P+1 pocket of IRAK-4, docked with a putative peptide substrate from the primary phosphorylation
site in the activation loop (379ARTQT) of IRAK-1 (shown in cyan sticks). Nitrogen atoms are blue, oxygen atoms are red, and sulfur atoms are
yellow.
(C) The P+1 site of phosphorylase kinase (PhK; PDB code: 2PHK); the activation loop is shown in red.
(D) Molecular surface representation of the substrate-binding site of PhK; a peptide substrate is shown as green sticks.comparison with PhK, where the P-2 residue from the
peptide substrate approached this region, we predict
that a large hydrophobic residue is preferred at P-2 for
the IRAK-4 substrate.
ATP-Binding Site and Tyrosine Gatekeeper
The core structure of the ATP-binding site for the IRAK-4
kinase domain is reminiscent of ATP- or inhibitor-bound
states of other protein kinases. However, a pivotal resi-
due at the center of the ATP-binding site, commonly
known as a ‘‘gatekeeper,’’ is unique for IRAK-4. The
term ‘‘gatekeeper’’ refers to a residue upstream of the
hinge that controls access to a pre-existing internal hy-
drophobic pocket at the back of the ATP-binding site
that ATP does not exploit. While nearly 20% of kinases
in the human kinome possess a smaller threonine resi-
due as a gatekeeper, and 40% of them have a large me-
thionine residue, IRAK-4 has a tyrosine residue, Tyr262,
at this position. When compared with more than 400
kinases in our in-house human kinome database, a tyro-
sine gatekeeper seems to be exclusive to the IRAK fam-ily of kinases. IRAK-1, IRAK-2, and IRAK-3 also have a
tyrosine as a gatekeeper. Interestingly, the structure re-
veals that the hydroxyl moiety of Tyr262 forms a direct
hydrogen-bond interaction with one of the carboxylate
oxygen atoms of the conserved glutamate, Glu233,
from helix aC (Figure 6).
The gatekeeper residue has been shown to play a
critical role in controlling kinase selectivity for various
small-molecule, ATP-competitive inhibitors. The back
hydrophobic pocket is more readily probed by a diverse
class of inhibitors for protein kinases with a smaller
gatekeeper residue like threonine. A bulky gatekeeper,
such as methionine or phenylalanine, seen for the major-
ity of protein kinases, makes the entrance to this pocket
more narrow. Here, with tyrosine at the gatekeeper posi-
tion, the back hydrophobic pocket is completely abol-
ished in IRAK-4. Tyr262 and Glu233 form a wall at the
end of the ATP-binding pocket (Figure 6).
One of the signature features of an active protein ki-
nase is the salt bridge between an absolutely conserved
glutamate residue from helix aC and the catalytic lysine
Structure
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(A) The Tyr262 gatekeeper interacts with conserved Glu233 from helix aC through a direct hydrogen bond (shown as a magenta, dotted line) in the
complex structure of IRAK-4 with compound 1 (shown as green sticks).
(B) The gatekeeper region of IRAK-4 in the presence of staurosporine (shown as yellow sticks).
(C and D) Molecular surface representation of the ATP-binding pocket in the presence of compound 1 and staurosporine, respectively.residue that coordinates the a- and b-phosphates of
ATP. In the cocrystal structure of IRAK-4 with compound
1, the catalytic-site lysine (Lys213) is attracted to the ni-
tro moiety of the compound. Thus, this classical ion-pair
interaction is not seen here. However, a Lys-Glu interac-
tion is maintained in the cocrystal structure with stauro-
sporine, where the conserved glutamate residue Glu233
plays a double role of interacting with both gatekeeper
Tyr262 and catalytic lysine Lys213 (Figure 6). Apparently,
the interaction between the gatekeeper and helixaC also
stabilizes helix aC in its active conformation.
Inhibitor-Binding Mode
Compound 1 was identified as a potent inhibitor for
IRAK-4 from our initial SAR chemistry effort following
high-throughput screening of a small-molecule library
(Powers et al., 2006). The well-resolved electron density
for compound 1 in the cocrystal structure reveals the in-
hibitor binding at the ATP-binding site, with the 3-nitro
phenyl ring positioned toward the back and the benz-
imidazole ring at the front (Figure 7A). The binding of
the inhibitor to IRAK-4 is mediated by numerous van
der Waals interactions and three hydrogen bonds. Inter-
estingly, the region where the adenine ring of ATP bindsis now occupied by the amide linker. The hydrogen bond
to the hinge region is made by the carbonyl accepting
a hydrogen bond from the backbone amide of Met265.
In the back of the pocket, the phenyl ring forms a partial
p-p aromatic stacking interaction with the gatekeeper,
Tyr262, and the nitro moiety makes a weak hydrogen
bond with the side-chain NH3+ of catalytic Lys213. The
benzimidazole ring binds toward the mouth region of
the kinase domain; the N-propanol substitution points
to the ATP ribose-binding area. Met192 of the phos-
phate-binding loop (P loop) makes close van der Waals
contacts with the benzimidazole ring from the top. The
trimethyl acetyl ester substitution points to the sol-
vent-exposed region; the carbonyl moiety makes the
third hydrogen bond by accepting a hydrogen bond
from Arg273 of helix aD in the C-terminal lobe. In sum-
mary, in addition to the common hinge hydrogen bond-
ing for the ATP-site inhibitors, compound 1 makes a few
special interactions with IRAK-4. These interactions
include the p-p stacking interaction with the tyrosine
gatekeeper and direct hydrogen bond interactions with
catalytic Lys213 and nonconserved Arg273 in helix aD.
The structure of the IRAK-4 kinase domain in complex
with staurosporine showed an almost identical binding
Crystal Structure of IRAK-4 Kinase
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(A) Inhibitor compound 1-binding mode in the ATP-binding site of IRAK-4. Electron density (shown in orange) of the inhibitor is contoured at
a level of 1s from a 2Fo 2 Fc map. Hydrogen bonds are shown as magenta, dotted lines.
(B) Staurosporine-binding mode in the ATP-binding site of IRAK-4; compound 1 is superimposed on it. Three hydrogen bonds are highlighted
with magenta, dotted lines.mode as other protein kinase-staurosporine cocrystal
structures (Lawrie et al., 1997; Prade et al., 1997; Zhao
et al., 2002; Zhu et al., 1999). Staurosporine makes
many van der Waals contacts and three hydrogen bonds
with IRAK-4 (Figure 7B). Two hydrogen bonds are made
to the hinge backbone by the NH and keto-oxygen of the
lactam ring, a typical ‘‘hinge plug.’’ The third hydrogen
bond is formed between the methylamino nitrogen of
the glycosidic group and the backbone carbonyl oxygen
of Ala315 from the catalytic loop.
Comparison of the IRAK-4 complex structures with
compound 1 and staurosporine shows that compound
1binds in partial overlap with staurosporine, but extends
more outward, to the front area of the ATP-binding
pocket where, again, ATP does not exploit (Figure 7B).
Unlike kinases with a small threonine gatekeeper, in
which inhibitors often penetrate deeply into the back of
the ATP-binding site and gain selectivity (Wang et al.,
1998; Wood et al., 2004; Zhu et al., 1999), IRAK-4 doesn’t
possess a deep pocket in the back due to the tyrosine
at the gatekeeper position. This results in compound 1
being bound more outwardly. However, the structure re-
veals a very unusual front pocket for IRAK-4. The loop
between helices aD and aE (residues 276–282) of IRAK-
4 sticks out of the C-terminal lobe and points to the N-
terminal lobe, forming a shield to the solvent area. The
normally flat and open front pocket in other kinases is
more like a wide groove in IRAK-4, with helix aD serving
as the floor, and its flanking loops as the walls (Figure 8).
In fact, the trimethyl acetyl ester substitution of com-
pound 1 extends into this unique pocket and makes
one hydrogen bond as well as a few van der Waals inter-
actions. The generally low sequence conservation in this
front pocket offers an appealing opportunity for the
design of selective inhibitors for IRAK-4.
Comparative Analysis
A comparative structural analysis of IRAK-4 by search-
ing the protein structure database with SSM (http://
www.ebi.ac.uk/msd-srv/ssm) (Krissinel and Henrick,2004), which is secondary structure matching based, re-
veals that IRAK-4 can be superimposed onto many pro-
tein kinases with a root-mean-square difference (rmsd)
in Ca positions of less than 2.0 A˚ and a Q-score (a com-
plex quality parameter of both the alignment length and
rmsd) of more than 0.4 with w250 residues. Interest-
ingly, all of the top matches with a Q-score of greater
than 0.45 are tyrosine kinases and include CDC42-asso-
ciated tyrosine kinase ACK1 (Lougheed et al., 2004),
interleukin-2 tyrosine kinase (Brown et al., 2004), LCK
(Yamaguchi and Hendrickson, 1996), Janus kinase 2
(JAK2) (Lucet et al., 2006), and c-Kit (Mol et al., 2003).
A sequence similarity search of the PDB database with
Blast (http://www.ncbi.nlm.nih.gov) (Altschul et al.,
1997) also shows that the majority of top scorers are
tyrosine kinases, such as Src family kinases and IRK.
Only one serine/threonine kinase, B-raf (Wan et al.,
2004), scores highly. Therefore, both sequence and
structure similarity analysis results suggest IRAK-4 is
Figure 8. Molecular Surface Representation of the Front Pocket of
the ATP-Binding Site in IRAK-4
The protruding loop aDE is shown in orange.
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1842Figure 9. Multiple Sequence Alignment of
IRAK-4 Homologs in the Gatekeeper and
Hinge Region and the Activation Segment
Sequences shown are human and mouse
IRAK-4; Arabidopsis thaliana PSB1, RLCK7,
APK1A, and APK1B; and human IRAK-1.
The gatekeeper is shown in red letters.more closely related to tyrosine kinase than serine/
threonine kinases.
A tyrosine gatekeeper seems to be the unique feature
for the IRAK family of kinases in our human kinome
database (432 kinases). A simple Blast search of the
Swissprot sequence database reveals that a few protein
kinases from a higher plant, Arabidopsis thaliana, are
close homologs of human IRAK-4, such as serine/threo-
nine protein kinase PBS1 (Swiderski and Innes, 2001),
the probable serine/threonine protein kinase RLCKVII
(Theologis et al., 2000), and Arabidopsis protein kinases
APK1A and APK1B (Hirayama and Oka, 1992; Swiderski
and Innes, 2001). These four kinases score just below
mouse IRAK-4 and even above human and mouse
IRAK-1. Moreover, they also have a tyrosine at the gate-
keeper position (Figure 9). In addition, several featured
residues in the activation segment are also similar to
those in IRAK-4. For example, the corresponding phos-
phate-interacting residue Arg334 (shown in bold), the
third residue downstream of the DFG motif (DFGXXR),
is also a positively charged lysine residue. Also, the res-
idue after the primary phosphorylation site threonine,
Arg347, is an arginine, and, finally, the residue after the
critical threonine in the P+1 pocket, Thr352, is tyrosine
or histidine (Figure 9). While PBS1 and RLCKVII are char-
acterized as putative serine/threonine kinases, APK1s
are shown to be able to phosphorylate serine, threonine,
and tyrosine residues, with tyrosine phosphorylation
occurring for a limited set of substrates.
Conclusions
IRAK-4 is a critical molecule mediating signals in both in-
nate and adaptive immune responses. It is a serine/thre-
onine kinase belonging to the TKL family of the human
kinome. Though IRAK-4 has been characterized func-
tionally as a serine/threonine kinase, the crystal struc-
ture described here, the first, to our knowledge, for the
IRAK family, revealed that IRAK-4 contains characteris-
tic structural features of both serine/threonine and tyro-
sine kinases, as well as additional unique attributes. The
activation loop and the phosphate ligand interactions
bear a close resemblance to those formed in tyrosine ki-
nases and are almost identical to those of IRK. To our
knowledge, the striking movement by helix aG and its
adjoining loops, which directly impacts substrate recog-
nition, has not been previously observed for other ki-
nases. Furthermore, the unique tyrosine gatekeeper in
IRAK-4 has 2-fold utility: (1) it stabilizes helix aC in the
active conformation, (2) and it abolishes the back hydro-
phobic pocket of the ATP-binding site.
Combining sequence and structure analysis with our
crystal structure data, we speculate that IRAK-4 might
have activity toward tyrosines in addition to serines
and threonines. The possible tyrosine kinase activity of
IRAK-4 is consistent with the recent discovery of the in-
volvement of IRAK-4 in T cell receptor (TCR) signaling.More recently, Suzuki et al. (2006) reported that IRAK-
4 also plays an important role in TCR-induced T cell
activation, particularly through the NF-kB pathway. Sev-
eral tyrosine kinases and subsequent tyrosine phos-
phorylation events of multiple intracellular proteins are
involved in the earlier events of TCR activation, including
activation of ZAP-70 tyrosine kinase. The new data re-
ported by Suzuki et al. (2006) suggest that IRAK-4 might
function through direct or indirect interaction with ZAP-
70 to activate PKCq, although the exact substrate of
IRAK-4 is not yet fully clear in this case. Our structural
finding that IRAK-4 is a possible dual-specificity kinase
should provide valuable insight into a better under-
standing of the role of IRAK-4 in both innate and ac-
quired immunity.
The IRAK-4 inhibitor cocrystal structure reveals that
the ATP-binding site in IRAK-4 has no deep pocket in
the back, but has a featured front pocket. This uniquely
shaped binding pocket grants an additional opportu-
nity for designing IRAK-4 inhibitors that confer high
selectivity.
Experimental Procedures
Protein Expression and Purification
The construct of the wild-type human IRAK-4 kinase domain (resi-
dues 154–460) was PCR cloned into pFastBac HTb vector (Invitro-
gen) containing an N-terminal His6 tag with a recombinant Tobacco
Etch Virus (rTEV) protease cleavage site. The recombinant bacmid
DNAs were transfected into Sf9 cells. After two rounds of amplifica-
tion, the baculovirus stock was transfected to Hi-5 cells. The cells
were harvested after 72 hr.
The cell pastes were lysed by microfluidizer and were then centri-
fuged at 20,000 rpm for 30 min. The supernatant was incubated with
Ni-NTA agarose beads (QIAGEN) and was then poured into a column.
After equilibration of the column with 50 mM Tris-HCl (pH 7.9),
250 mM NaCl, 10% glycerol, 10 mM imidazole, and 5 mM b-mercap-
toethanol, the protein was eluted with 250 mM imidazole in the
buffer. The Ni-eluted IRAK-4 fractions were incubated with rTEV pro-
tease at 4C overnight to cleave the N-terminal His6 tag. The mixture
was loaded onto a Ni-NTA column to remove the His6 tag and the
rTEV protease, which was also His6 tagged. The protein was then
further purified by using an anion-exchange column of Mono-Q
(Pharmacia) and was eluted with a linear salt gradient of 50–1000
mM NaCl in 50 mM Tris-HCl (pH 7.9), 10% glycerol, 1 mM EDTA,
and 1 mM DTT. Finally, a gel-filtration column of Superdex 75 (Phar-
macia) was used. The purified protein was then concentrated to
1 mg/ml in gel-filtration buffer of 50 mM HEPES (pH 7.6), 250 mM
NaCl, 10% glycerol, and 2 mM DTT.
Chemicals
Staurosporine was purchased from Calbiochem (La Jolla, CA). Com-
pound 1 was synthesized and purified as previously described
(Powers et al., 2006). Both inhibitors were dissolved to 30 mM in
DMSO and were stored at 220C until needed.
Crystallization
The purified protein at 1 mg/ml was incubated with 5-fold excessof in-
hibitors for2–6hr before it was concentrated tow4 mg/ml. Small crys-
tals were grown at 20C by either hanging or sitting drop from 2.5 ml
protein solution plus 2.5 ml well solution containing 2.6–2.9 M ammo-
nium sulfate (Hampton Research) in 0.1 M HEPES (pH 6.4–7.5).
Crystal Structure of IRAK-4 Kinase
1843Larger crystals (w0.3 3 0.3 3 0.1 mm) were normally obtained by
either micro- or macroseeding. The crystals were transferred into
a well solution that contained an additional 20% (w/v) of ethylene
glycol and were then flash frozen in liquid nitrogen.
Data Collection, Structure Determination, and Refinement
X-ray diffraction data sets were collected on a Rigaku RU-H3RHB
generator/RAXIS-IV detector, on synchrotron sources of the Ad-
vanced Light Source beamline 5.0.2 in Berkeley, CA and Advanced
Photo Source (APS) beamline SBC-19IND in Argonne, Il. The best
diffraction resolution of 2.0 A˚ was obtained at APS. All data were
integrated with MOSFLM and were scaled with SCALA in CCP4
(CCP4, 1994). Cocrystals of the IRAK-4 kinase domain with com-
pound 1 or staurosporine grew in space group C2, with slightly dif-
ferent cell constants, i.e., a = 145.3, b = 141.3, c = 88.4, b = 125.8 and
a = 141.5, b = 139.7, c = 87.7, b = 123.8, respectively. Molecular re-
placement failed to yield an interpretable electron density map
when various kinase structures were used as a search model. The
IRAK-4 kinase domain structure was solved by SAD phasing from
a mercury derivative of para-chloromercuribenzoic acid, sodium
salt (PCMBS) (Hampton Research) with a home-source X-ray dif-
fraction data set at 3.2 A˚ with l = 1.54 A˚ by using SOLVE (Terwilliger
and Berendzen, 1999) and SHARP (de la Fortelle and Bricogne,
1997). NCS averaging with the program DM in CCP4 was able to pro-
duce a traceable map of high quality. A model was built by using the
program O (Jones et al., 1991) and Quanta (Accelrys) and was re-
fined with REFMAC5 in CCP4 and CNX (Brunger et al., 1998). Subse-
quent model building and refinement cycles were carried out in
Quanta, REFMAC5, and CNX. For all structures, the stereochemistry
of the models was inspected by using PROCHECK (Laskowski et al.,
1993).
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